Annovis Bio Regains NYSE Listing Compliance
Annovis Bio has regained full compliance with NYSE continued listing standards, resolving a non-compliance notice issued in March 2025. The company achieved this milestone in 12 months, well ahead of the 18-month cure period granted by the exchange, by restoring its market capitalization and stockholders' equity above the $50 million thresholds.
Key figures
- Equity threshold
- $50 million
- Time to compliance
- 12 months
- Cure period granted
- 18 months
- Market cap threshold
- $50 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.